Lexington, KY | October 25, 2021—NX Development Corp. exhibited at the 2021 Congress of Neurological Surgeons (CNS) Annual Meeting in Austin, TX. This meeting could be described as a complete success due to the high in-person attendance, numerous...
T.J. Stalvey Joins NX Development Corp. (NXDC) as Vice President of Clinical Development and Medical Affairs
LEXINGTON, KY |GlobeNewswire| April 15, 2021 — NX Development Corp. (NXDC), a life-sciences company wholly owned by photonamic GmbH & Co. KG., today announced that Tracy Jerome “T.J.” Stalvey has been named Vice President of Clinical Operations.
NX Development Corp. (NXDC) Receives FDA Orphan-Drug Designation for Gleolan® (aminolevulinic acid HCl) in Meningioma
Lexington, KY, Jan. 12, 2021 (GLOBE NEWSWIRE) — NX Development Corp. (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced FDA orphan-drug designation for Gleolan, an optical imaging agent for the...
NX DEVELOPMENT CORP. (NXDC) LAUNCHES GLEOLAN™ (AMINOLEVULINIC ACID HCL) MENINGIOMA PHASE III CLINICAL TRIAL (NXDC-MEN-301)
LEXINGTON, KY |GlobeNewswire| November 17, 2020 — NX Development Corp (NXDC), a life sciences company wholly owned by photonamic GmbH & Co. KG., today announced the enrollment of the first patient in a Phase III multicenter study of Gleolan to...
Lexington-Based NX Development Corp (NXDC) Announces Baptist Health Lexington is First Hospital in Kentucky to Use Breakthrough Imaging Agent for Brain Tumor Visualization
Dr. Christian Ramsey first neurosurgeon in state to use Gleolan™ for enhanced visualization of high-grade gliomas/glioblastoma